Specifications
- Purity
- ≥98%
- Appearance
- White to off-white powder
- Identity
- IR
Properties
- Solvents
- water (3.3 mg/ml), acidic and basic solutions
Documentation
- Safety Data Sheet (SDS)
- CDX D0465 MSDS.pdf
Available from stock
3,4-Dihydroxy-L-phenylalanine
- SKU
- D0465
Category: Metabolites
- Synonyms
- 3-(3,4-Dihydroxyphenyl)-L-alanine , L-DOPA , 3-Hydroxy-L-tyrosine , Levodopa
- 59-92-7
- CAS-Number
- C9H11NO4
- Molecular Formula
- 197.19
- Molecular Weight
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
- Shipping
- AMBIENT
- Short Term Storage
- RT
- Long Term Storage
- RT
- Handling Advice
- Protect from light and moisture.
- Use / Stability
- Stable for at least 2 years after receipt when stored at RT.
- Hazard statements
- H302-H315-H319-H335
- Precautionary statements
- P301 + P312 + P330-P305 + P351 + P338
- GHS Symbol
- GHS07
- Signal word
- Warning
- Transportation
- Not dangerous goods
- Description
- Metabolic precursor of the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline), which are collectively known as catecholamines. This amino acid is produced from L-tyrosine by tyrosine hydroxylase and metabolized by catechol-O-methyl transferase (COMT). L-DOPA is capable of crossing the blood brain barrier where it is converted to dopamine. Formulations containing L-DOPA have been used to increase dopamine concentrations in the brain as a treatment for Parkinson’s disease and stroke recovery. Mediates neurotrophic factor release by the brain and CNS. Used for the treatment of Parkinson’s disease and dopamine-responsive dystonia. In addition it is used, as a cell adhesion molecule in serum-free cultures of anchorage-dependent mammalian cells, to prevent surfaces from fouling by bonding antifouling polymers to a susceptible substrate or to stain melanocytes.
- Smiles
- OC1=C(O)C=CC(C[C@H](N)C(O)=O)=C1
- InChi Key
- WTDRDQBEARUVNC-LURJTMIESA-N
- References
- (1) O. Hornykiewicz, Life Sci. 15, 1249 (1974) (Review) , (2) Y. Misu, et al., Adv. Pharmacol. 32, 427 (1995) (Review) , (3) J.G. Nutt, Adv. Neurol. 69,493 (1996) (Review) , (4) R.M. Kostrzewa, et al., Amino Acids 23, 57 (2002) (Review) , (5) N.B. Mercuri & G. Bernardi, Trends Pharmacol. Sci. 26, 341 (2005) (Review) , (6) M.A. Mena, et al., Curr. Top. Med. Chem. 9, 880 (2009) (Review) , (7) H.I. Berends, et al., Eur. J. Phys. Rehabil. Med. 45, 621 (2009) (Review) , (8) H. Iderberg, et al., Neuroscience 211, 13 (2012) (Review) , (9) Y. Huang, et al., Electrochim. Acta 113, 564 (2013) , (10) P. Huot, et al., Pharmacol. Rev. 65, 171 (2013) (Review) , (11) J. Tang, et al., Cytotechnology 66, 891 (2014) , (12) G. Fichman, et al., ACS Nano. 8, 7220 (2014) , (13) M.M. Conti, et al., Neurosci. Biobehav. Rev. (Epub ahead of print) (2018) (Review)
- InChi
- InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1
Metabolic precursor of the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline), which are collectively known as catecholamines. This amino acid is produced from L-tyrosine by tyrosine hydroxylase and metabolized by catechol-O-methyl transferase (COMT). L-DOPA is capable of crossing the blood brain barrier where it is converted to dopamine. Formulations containing L-DOPA have been used to increase dopamine concentrations in the brain as a treatment for Parkinson’s disease and stroke recovery. Mediates neurotrophic factor release by the brain and CNS. Used for the treatment of Parkinson’s disease and dopamine-responsive dystonia. In addition it is used, as a cell adhesion molecule in serum-free cultures of anchorage-dependent mammalian cells, to prevent surfaces from fouling by bonding antifouling polymers to a susceptible substrate or to stain melanocytes.
Additional information
| Synonyms | 3-(3,4-Dihydroxyphenyl)-L-alanine, L-DOPA, 3-Hydroxy-L-tyrosine, Levodopa |
|---|---|
| Purity | ≥98% |
| Appearance | White to off-white powder |
| CAS-Number | 59-92-7 |
| Molecular Formula | C9H11NO4 |
| Molecular Weight | 197.19 |
| Identity | IR |
| Solvents | water (3.3 mg/ml), acidic and basic solutions |
| Smiles | OC1=C(O)C=CC(C[C@H](N)C(O)=O)=C1 |
| InChi Key | WTDRDQBEARUVNC-LURJTMIESA-N |
| Shipping | AMBIENT |
| Short Term Storage | RT |
| Long Term Storage | RT |
| Handling Advice | Protect from light and moisture. |
| Use / Stability | Stable for at least 2 years after receipt when stored at RT. |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P301 + P312 + P330-P305 + P351 + P338 |
| GHS Symbol | GHS07 |
| Signal word | Warning |
| Transportation | Not dangerous goods |
| References | (1) O. Hornykiewicz, Life Sci. 15, 1249 (1974) (Review), (2) Y. Misu, et al., Adv. Pharmacol. 32, 427 (1995) (Review), (3) J.G. Nutt, Adv. Neurol. 69,493 (1996) (Review), (4) R.M. Kostrzewa, et al., Amino Acids 23, 57 (2002) (Review), (5) N.B. Mercuri & G. Bernardi, Trends Pharmacol. Sci. 26, 341 (2005) (Review), (6) M.A. Mena, et al., Curr. Top. Med. Chem. 9, 880 (2009) (Review), (7) H.I. Berends, et al., Eur. J. Phys. Rehabil. Med. 45, 621 (2009) (Review), (8) H. Iderberg, et al., Neuroscience 211, 13 (2012) (Review), (9) Y. Huang, et al., Electrochim. Acta 113, 564 (2013), (10) P. Huot, et al., Pharmacol. Rev. 65, 171 (2013) (Review), (11) J. Tang, et al., Cytotechnology 66, 891 (2014), (12) G. Fichman, et al., ACS Nano. 8, 7220 (2014), (13) M.M. Conti, et al., Neurosci. Biobehav. Rev. (Epub ahead of print) (2018) (Review) |
| InChi | InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1 |
| Quantity | 25 g, 100 g, Bulk |
